Kezar Life Sciences (NASDAQ:KZR) Earns Market Perform Rating from William Blair

William Blair restated their market perform rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research report sent to investors on Wednesday,RTT News reports.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Stock Down 0.8 %

NASDAQ:KZR opened at $7.46 on Wednesday. Kezar Life Sciences has a 12-month low of $5.20 and a 12-month high of $11.35. The company’s 50-day moving average is $7.20 and its two-hundred day moving average is $6.83. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 7.65.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, topping the consensus estimate of ($3.03) by $0.25. Research analysts expect that Kezar Life Sciences will post -6.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

A number of hedge funds have recently bought and sold shares of KZR. Vanguard Group Inc. grew its holdings in shares of Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after purchasing an additional 30,740 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Kezar Life Sciences by 3.6% during the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after purchasing an additional 64,356 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Kezar Life Sciences in the first quarter worth about $1,588,000. Stonepine Capital Management LLC increased its stake in Kezar Life Sciences by 42.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after buying an additional 440,853 shares during the period. Finally, Ikarian Capital LLC raised its position in shares of Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.